Chen Leiyang, Zhang Xiuxiu, Shi Peizhi
Department of Cardiology, Pujiang Branch, The First Affiliated Hospital of Zhejiang University, Jinhua, 321000, China.
Eur J Med Res. 2025 Nov 7;30(1):1081. doi: 10.1186/s40001-025-03324-6.
Sepsis is life-threatening inflammatory disease, and its pathogenesis and prognostic factors remain unclear. In addition, the symptoms and signs of sepsis patients lack specificity, which makes the diagnosis, treatment and prognosis evaluation of sepsis extremely difficult. Recently, with the emergence and development of detection technologies, various sepsis-related biomarkers have emerged. Biomarkers could be considered as indicators of either infection or dysregulated host response or response to treatment and/or aid clinicians to prognosticate patient risk. Therefore, searching for reliable biomarkers and evaluating their role in sepsis is envisaged to aid clinical decision-making. This article reviews the advances in research on sepsis biomarkers and their application in the early prediction of organ dysfunction to improve our understanding of current sepsis biomarkers and provide a reference for the application of biomarkers in the clinical diagnosis, treatment, and prognosis of sepsis. Besides, we propose that the combining multiple biomarkers is expected to be a more accurate and comprehensive strategy to evaluate the condition and prognosis of sepsis patients.
脓毒症是一种危及生命的炎症性疾病，其发病机制和预后因素仍不清楚。此外，脓毒症患者的症状和体征缺乏特异性，这使得脓毒症的诊断、治疗和预后评估极其困难。近年来，随着检测技术的出现和发展，各种脓毒症相关生物标志物不断涌现。生物标志物可被视为感染、宿主反应失调或对治疗反应的指标，和/或帮助临床医生预测患者风险。因此，寻找可靠的生物标志物并评估它们在脓毒症中的作用，有望辅助临床决策。本文综述了脓毒症生物标志物的研究进展及其在器官功能障碍早期预测中的应用，以增进我们对当前脓毒症生物标志物的理解，并为生物标志物在脓毒症临床诊断、治疗和预后中的应用提供参考。此外，我们提出联合多种生物标志物有望成为评估脓毒症患者病情和预后更准确、更全面的策略。
